Press Releases Immunovant, Inc.

Equities

IMVT

US45258J1025

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
28.86 ^USD	+0.28%		+6.22%	-31.50%

04-20	Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	MT
04-20	Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunovant Awarded U.S. Patent for IMVT-1402	03-12	AQ
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023	02-12	AQ
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-03	AQ
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	12-20	AQ
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	11-28	AQ
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	11-28	AQ
Immunovant to Present at Upcoming Investor Conferences	11-13	AQ
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023	11-09	AQ
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares	23-10-02	AQ
Immunovant Announces Pricing of $450 Million Common Stock Financing	23-09-27	AQ
Immunovant Announces Proposed Offering of $300 Million of Common Stock	23-09-26	AQ
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results	23-09-26	AQ
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023	23-09-25	AQ
Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors	23-09-20	PR
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023	23-08-10	AQ
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023	23-05-22	AQ
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	23-05-01	AQ
IMMUNOVANT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-03-27	AQ
IMMUNOVANT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-02-03	AQ
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022	23-02-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immunovant, Inc.

Equities

IMVT

US45258J1025

Press Releases

Filters